Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study.
- DOI
- 10.1136/jitc-2025-011918
- Published
- 2025 Oct 5
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2025-011918,
title = {Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study.},
author = {Lonardi S and Ługowska I and O'Donnell A and Jackson C and Latten-Jansen LM and North R and Bahleda R and Garrido M and Santoro A and Chacon MR and Li L and Joseph D and Vezina HE and Aras U and Bennett B and Perumal D and Gurm B and Ng WT and Harvey RD and Trigo J and Calvo A},
year = {2025},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2025-011918},
url = {https://doi.org/10.1136/jitc-2025-011918}
}RIS
TY - JOUR TI - Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study. AU - Lonardi S AU - Ługowska I AU - O'Donnell A AU - Jackson C AU - Latten-Jansen LM AU - North R AU - Bahleda R AU - Garrido M AU - Santoro A AU - Chacon MR AU - Li L AU - Joseph D AU - Vezina HE AU - Aras U AU - Bennett B AU - Perumal D AU - Gurm B AU - Ng WT AU - Harvey RD AU - Trigo J AU - Calvo A PY - 2025 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2025-011918 UR - https://doi.org/10.1136/jitc-2025-011918 ER -
APA
S, L., I, Ł., A, O., C, J., LM, L., R, N., R, B., M, G., A, S., MR, C., L, L., D, J., HE, V., U, A., B, B., D, P., B, G., WT, N., RD, H., J, T., & A, C. (2025). Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2025-011918
Source records
- pubmed · retrieved 2026-09-25T19:58:30.142Z